# GANEA — Ganglion Sentinelle et Chimiothérapie Néoadjuvante (French Multicenter)

**Autores:** Classe JM, Bordes V, Campion L, Mignotte H, Dravet F, Leveque J, Sagan C, Dupre PF, Body G, Giard S
**Revista:** Journal of Clinical Oncology (2009) (publicado online 2008)
**PMID:** 19114697 | **PMCID:** —
**DOI:** [10.1200/JCO.2008.18.3228](https://doi.org/10.1200/JCO.2008.18.3228)
**Fuente:** PubMed (abstract only — full text vía DOI/institución)

## Relevancia
Estudio prospectivo multicéntrico francés que evaluó SLNB después de NAC en cáncer de mama localmente avanzado. Demostró factibilidad pero con mejores resultados en pacientes inicialmente cN0 (detección 94.6%) que cN+ (81.5%). Precursor de los GANEA-2 y los grandes ensayos posteriores.

## Abstract

**Purpose:** To determine the detection rate, the false-negative rate, and the accuracy of sentinel lymph node (SLN) detection after neoadjuvant chemotherapy (NAC) for advanced breast cancer.

**Methods:** A prospective multicentric study was initiated to evaluate the results of SLN biopsy with the combined method after NAC for advanced large operable breast cancer.

**Results:** From September 2003 to March 2007, **195 patients** enrolled from 12 institutions. The **detection rate was 90%** (176/195), and the **false-negative rate was 11.5%** (6/52). Patients without axillary palpable nodes (N0) before NAC had a **better detection rate** compared with cN1 (94.6% vs 81.5%; p=0.008). The false-negative rate was not correlated with clinical nodal status before NAC (9.4% vs 15%; p=0.66).

**Conclusion:** This study confirms the feasibility of SLN biopsy after NAC in the case of large operable breast cancer. The detection rate, FNR, and accuracy do not differ from those obtained in early breast cancer without NAC.

## Acceso
Artículo no disponible en PMC. Acceder vía [DOI](https://doi.org/10.1200/JCO.2008.18.3228) o suscripción institucional.

---
*Datos de PubMed. Citar: doi 10.1200/JCO.2008.18.3228*
